LSE · ABDX.L
Abingdon Health Plc
£0.09£0.00 (0.0%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 30.77% below the high.
Loading market information…
LSE · IXI.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 04:27 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
IXICO plc’s quoted price sits in the upper half of its reported 52-week range, 9.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow IXICO plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, from acquisition and processing to in-depth analysis and comprehensive reporting. They leverage proprietary technology platforms like Assessa, a secure digital tool that aids clinical decision-making for patient selection and post-market monitoring, and TrialTracker, which streamlines intricate imaging workflows, handling everything from initial image uploads and quality control to expert analysis, interpretation, and final data delivery within clinical research. IXICO's expertise is concentrated on neurological disorders, including Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and various rare neurological diseases. Their services encompass not only the collection, optimization, and analytics for rare neurological disorders but also drug development analytics, specialized imaging operations, post-market surveillance support, and expert consultancy. The company delivers comprehensive, end-to-end services for clinical trials, covering initial trial design and consultation, meticulous project management, imaging site setup and management, robust data management, expert image reading and analysis, and guidance on regulatory pathways.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
£0.09£0.00 (0.0%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 30.77% below the high.
£0.02-£0.00 (-3.95%)
Genflow Biosciences Plc’s quoted price sits in the lower half of its reported 52-week range, 41.51% below the high.
£0.06+£0.00 (+1.6%)
Fusion Antibodies plc’s quoted price sits in the lower half of its reported 52-week range, 68.25% below the high.
£0.06+£0.00 (+2.65%)
OptiBiotix Health Plc’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
